The goal of this randomised controlled trial is to determine the effect of consuming a multistrain probiotic OMNi-BiOTiC® Hetox on improving the healing, pain management, and postsurgical complications after neurosurgery. The main question it aims to answer is: • Is the multistrain probiotic OMNi-BiOTiC® Hetox effective in in improving patient-reported disability after neurosurgery? Researchers will compare the probiotic group and the placebo group to determine if the healing is significantly different between the groups.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
110
OMNi-BiOTiC® Hetox multistrain probiotic
Placebo
University Medical Centre Maribor
Maribor, Slovenia
RECRUITINGChange from baseline in Oswestry Disability Index (ODI) at 3 months
Functional disability will be assessed using the Oswestry Disability Index (ODI, version 2.1a; range 0-100, higher = greater disability). The primary outcome is the mean change in ODI from baseline to 3 months post-neurosurgery.
Time frame: 4 weeks supplementation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.